Publication:
Risk of Secondary Progressive Multiple Sclerosis After Early Worsening of Disability

dc.authorscopusid57865209700
dc.authorscopusid55028512500
dc.authorscopusid7006700571
dc.authorscopusid7005179252
dc.authorscopusid56549046700
dc.authorscopusid57222512447
dc.authorscopusid6602078414
dc.authorwosidPatti, Francesco/C-3300-2011
dc.authorwosidEichau, Sara/Aaa-8145-2019
dc.authorwosidLugaresi, Alessandra/C-7743-2012
dc.authorwosidTerzi̇, Murat/Aaa-1284-2021
dc.authorwosidLugaresi, Alessana/C-7743-2012
dc.authorwosidOnofrj, Marco/K-7710-2016
dc.authorwosidSoysal, Aysun/Aax-7696-2021
dc.contributor.authorDzau, Winston
dc.contributor.authorSharmin, Sifat
dc.contributor.authorPatti, Francesco
dc.contributor.authorIzquierdo, Guillermo
dc.contributor.authorEichau, Sara
dc.contributor.authorPrat, Alexandre
dc.contributor.authorKalincik, Tomas
dc.contributor.authorIDLugaresi, Alessana/0000-0003-2902-5589
dc.contributor.authorIDOnofrj, Marco/0000-0002-0480-2495
dc.contributor.authorIDPrat, Alexane/0000-0001-6188-0580
dc.date.accessioned2025-12-11T01:29:33Z
dc.date.issued2023
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Kalincik, Tomas] Univ Melbourne, Dept Med, CORe, Melbourne, Vic 3050, Australia; [Dzau, Winston; Buzzard, Katherine; Kalincik, Tomas] Royal Melbourne Hosp, Neuroimmunol Ctr, Dept Neurol, Parkville, Vic, Australia; [Dzau, Winston; Sharmin, Sifat; Kalincik, Tomas] Univ Melbourne, Dept Med, CORe, Melbourne, Vic, Australia; [Patti, Francesco] Univ Catania, Dept Surg & Med Sci & Adv Technol GF Ingrassia, Neurosci, Catania, Italy; [Patti, Francesco] Univ Catania, Multiple Sclerosis Ctr, Catania, Italy; [Izquierdo, Guillermo; Eichau, Sara] Hosp Univ Virgen Macarena, Dept Neurol, Seville, Andalucia, Spain; [Prat, Alexandre; Girard, Marc; Duquette, Pierre] CHUM, MS Ctr, Montreal, PQ, Canada; [Prat, Alexandre; Girard, Marc; Duquette, Pierre] Univ Montreal, Fac Med, Montreal, PQ, Canada; [Onofrj, Marco] Gabriele Annunzio Univ Chieti & Pescara, Dept Neurosci Imaging & Clin Sci, Dept Sci, Chieti, Italy; [Lugaresi, Alessandra] Univ Bologna, Dipartimento Sci Biomed & Neuromotorie, Bologna, Italy; [Lugaresi, Alessandra] IRCCS Ist Sci Neurol Bologna, UOSI Riabilitaz Sclerosi Multipla, Bologna, Italy; [Ozakbas, Serkan] Dokuz Eylul Univ, Fac Med, Izmir, Turkiye; [Gerlach, Oliver] Zuyderland Med Ctr, Dept Neurol, Sittard Geleen, Netherlands; [Gerlach, Oliver] Univ Maastricht, Sch Mental Hlth & Neurosci, Maastricht, Netherlands; [Boz, Cavit] Karadeniz Tech Univ, Med Fac, Trabzon, Turkiye; [Duquette, Pierre] CIUSSS Ctr Ouest De Iile De Montreal, Dept Neurol, Montreal, PQ, Canada; [Terzi, Murat] Ondokuz Mayis Univ, Med Fac, Samsun, Turkiye; [Amato, Maria Pia] Univ Florence, Dept NEUROFARBA, Florence, Italy; [La Spitaleri, Daniele] Azienda Osped Rilievo Nazl & Alta Special San Gius, Dept Neurol, Avellino, Italy; [Ramo-Tello, Cristina] Hosp Badalona Germans Trias & Pujol, Dept Neurol, Badalona, Spain; [Maimone, Davide] Azienda Osped Rilievo Nazl & Alta Specializzaz Gar, UO Neurol, Catania, Sicilia, Italy; [Cartechini, Elisabetta] Azienda Sanit Unica Reg, UOC Neurol, Ancona, Italy; [Buzzard, Katherine; Skibina, Olga] Box Hill Hosp, Dept Neurol, Box Hill, Vic, Australia; [Buzzard, Katherine; Skibina, Olga] Monash Univ, Dept Med, Clayton, Vic, Australia; [Skibina, Olga; van der Walt, Anneke; Butzkueven, Helmut] The Alfred, Dept Neurol, Melbourne, Vic, Australia; [van der Walt, Anneke; Butzkueven, Helmut] Monash Univ, Cent Clin Sch, Clayton, Vic, Australia; [Iuliano, Gerardo] Azienda Osped Univ San Giovanni Dio & Ruggi Aragon, Dept Neurol, Salerno, Italy; [Soysal, Aysun] Bakirkoy Educ & Res Hosp Psychiat & Neurol Dis, Dept Neurol, Istanbul, Turkiyeen_US
dc.descriptionLugaresi, Alessana/0000-0003-2902-5589; Onofrj, Marco/0000-0002-0480-2495; Prat, Alexane/0000-0001-6188-0580;en_US
dc.description.abstractBackgroundWhether progression independent of relapse activity (PIRA) heralds earlier onset of secondary progressive multiple sclerosis (SPMS) and more rapid accumulation of disability during SPMS remains to be determined. We investigated the association between early PIRA, relapse-associated worsening (RAW) of disability and time to SPMS, subsequent disability progression and their response to therapy. MethodsThis observational cohort study included patients with relapsing-remitting multiple sclerosis (RRMS) from the MSBase international registry across 146 centres and 39 countries. Associations between the number of PIRA and RAW during early multiple sclerosis (MS) (the initial 5 years of MS onset) were analysed with respect to: time to SPMS using Cox proportional hazards models adjusted for disease characteristics; and disability progression during SPMS, calculated as the change of Multiple Sclerosis Severity Scores over time, using multivariable linear regression. Results10 692 patients met the inclusion criteria: 3125 (29%) were men and the mean MS onset age was 32.2 years. A higher number of early PIRA (HR=1.50, 95% CI 1.28 to 1.76, p<0.001) and RAW (HR=2.53, 95% CI 2.25 to 2.85, p<0.001) signalled a higher risk of SPMS. A higher proportion of early disease-modifying therapy exposure (per 10%) reduced the effect of early RAW (HR=0.94, 95% CI 0.89 to 1.00, p=0.041) but not PIRA (HR=0.97, 95% CI 0.91 to 1.05, p=0.49) on SPMS risk. No association between early PIRA/RAW and disability progression during SPMS was found. ConclusionsEarly disability increase during RRMS is associated with a greater risk of SPMS but not the rate of disability progression during SPMS. The deterioration associated with early relapses represents a potentially treatable risk factor of SPMS.en_US
dc.description.sponsorshipMerck; Biogen; Novartis; Bayer-Schering; Sanofi-Genzyme; Tevaen_US
dc.description.sponsorshipTK and WD had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The MSBase Foundation is a not-for-profit organization that receives support from Merck, Biogen, Novartis, Bayer-Schering, Sanofi-Genzyme and Teva. All aspects of the study were completed independent and separate from the MSBase funders - including design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication. We thank the MSBase Operations Team, Ms Charlotte Sartori, Ms Pamela Farr, Ms Rein Moore, Mr Dusko Stupar, Ms Cynthia Tang and Ms Sonya Smirnova. Further acknowledgements found in Appendix A.en_US
dc.description.woscitationindexScience Citation Index Expanded
dc.identifier.doi10.1136/jnnp-2023-331748
dc.identifier.endpage991en_US
dc.identifier.issn0022-3050
dc.identifier.issn1468-330X
dc.identifier.issue12en_US
dc.identifier.pmid37414538
dc.identifier.scopus2-s2.0-85166407723
dc.identifier.scopusqualityQ1
dc.identifier.startpage984en_US
dc.identifier.urihttps://doi.org/10.1136/jnnp-2023-331748
dc.identifier.urihttps://hdl.handle.net/20.500.12712/44061
dc.identifier.volume94en_US
dc.identifier.wosWOS:001031822500001
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.ispartofJournal of Neurology Neurosurgery and Psychiatryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMultiple Sclerosisen_US
dc.titleRisk of Secondary Progressive Multiple Sclerosis After Early Worsening of Disabilityen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files